Kidney Cancer Drug, Axitinib, Might Help Attack Other Types of Cancer
Researchers at the University of Bergen are taking a second look at the kidney cancer drug, axitinib, as a potential treatment for other cancers. Their study, published in Proceedings of the National Academy of Sciences, began with mapping the effects of 500 known drugs to identify off-target effects. Off-target effects are beneficial side effects outside of the scope of the drug’s original purpose.
Axitinib stood out among the drugs because it halts a type of Wnt signaling, a communication method used between cells to encourage mutation. Cell mutation is the cause of about 90 percent of all cancers and halting the mutation signals could also halt the development of many types of cancers.
Several other medications showed beneficial off-target effects that doctors might soon use in the fight against cancer. The researchers are now looking at these multipurpose drugs for further testing and eventually inclusion in the treatment protocols for other cancers.
Stopping the cell mutation mechanisms is only one step on the road to a cancer cure. While this discovery is not a cure, it is a strong contribution in the arsenal of treatments doctors have developed to halt or slow cancer development and destruction.
Severe Effects of Cancer Can Qualify You for Social Security Disability Benefits
The Social Security Administration considers many cancers severely disabling conditions when they reach a certain stage of development or cause certain impairments. If you have a cancer diagnosis and can no longer work and earn an income due to your illness, you might qualify for Social Security disability benefits.
Contact the disability advocates at the Disability Help Group for help with your SSDI claim. Call 800-800-2009 to schedule a consultation.